MX2022004699A - Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. - Google Patents
Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.Info
- Publication number
- MX2022004699A MX2022004699A MX2022004699A MX2022004699A MX2022004699A MX 2022004699 A MX2022004699 A MX 2022004699A MX 2022004699 A MX2022004699 A MX 2022004699A MX 2022004699 A MX2022004699 A MX 2022004699A MX 2022004699 A MX2022004699 A MX 2022004699A
- Authority
- MX
- Mexico
- Prior art keywords
- tucatinib
- capecitabine
- trastuzumab
- combination
- breast cancer
- Prior art date
Links
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 title abstract 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 3
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 title abstract 3
- 229960004117 capecitabine Drugs 0.000 title abstract 3
- 229960000575 trastuzumab Drugs 0.000 title abstract 3
- 229950003463 tucatinib Drugs 0.000 title abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En un aspecto, la presente descripción se refiere a un método para tratar o mejorar los efectos de un cáncer de mama con sobreexpresión de HER2 en un sujeto mediante la administración de una combinación de tucatinib, capecitabina y trastuzumab. En algunas modalidades, los métodos proporcionados en este documento son útiles para tratar o mejorar los efectos de una metástasis cerebral asociada con cáncer de mama con sobreexpresión de HER2 en un sujeto mediante la administración de una combinación de tucatinib, capecitabina y trastuzumab.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923659P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/056489 WO2021080983A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004699A true MX2022004699A (es) | 2022-08-08 |
Family
ID=73598175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004699A MX2022004699A (es) | 2019-10-21 | 2020-10-20 | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240092936A1 (es) |
| EP (1) | EP4048275A1 (es) |
| JP (1) | JP2022553041A (es) |
| KR (1) | KR20220086627A (es) |
| CN (1) | CN114746094A (es) |
| AU (1) | AU2020370058A1 (es) |
| CA (1) | CA3156820A1 (es) |
| IL (1) | IL292332A (es) |
| MX (1) | MX2022004699A (es) |
| WO (1) | WO2021080983A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200014298A (ko) | 2017-04-28 | 2020-02-10 | 시애틀 지네틱스, 인크. | Her2 양성 암의 치료 |
| CN115252793A (zh) * | 2022-08-15 | 2022-11-01 | 新疆医科大学第三附属医院 | 一种乳腺癌靶向抑制因子及其在乳腺癌治疗中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| JPH07507768A (ja) | 1992-03-12 | 1995-08-31 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | Ａｃｔｈ含有マイクロスフェアの制御放出 |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| CN108498465B (zh) | 2011-10-14 | 2022-05-17 | 阵列生物制药公司 | ErbB2(HER2)抑制剂的固态分散体 |
| SG11201401460PA (en) | 2011-10-14 | 2014-09-26 | Array Biopharma Inc | POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| KR20200014298A (ko) * | 2017-04-28 | 2020-02-10 | 시애틀 지네틱스, 인크. | Her2 양성 암의 치료 |
-
2020
- 2020-10-20 EP EP20812457.8A patent/EP4048275A1/en active Pending
- 2020-10-20 IL IL292332A patent/IL292332A/en unknown
- 2020-10-20 AU AU2020370058A patent/AU2020370058A1/en active Pending
- 2020-10-20 KR KR1020227016776A patent/KR20220086627A/ko unknown
- 2020-10-20 WO PCT/US2020/056489 patent/WO2021080983A1/en unknown
- 2020-10-20 CN CN202080077966.9A patent/CN114746094A/zh active Pending
- 2020-10-20 US US17/768,290 patent/US20240092936A1/en active Pending
- 2020-10-20 JP JP2022523453A patent/JP2022553041A/ja active Pending
- 2020-10-20 CA CA3156820A patent/CA3156820A1/en active Pending
- 2020-10-20 MX MX2022004699A patent/MX2022004699A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020370058A1 (en) | 2022-04-14 |
| US20240092936A1 (en) | 2024-03-21 |
| WO2021080983A1 (en) | 2021-04-29 |
| CA3156820A1 (en) | 2021-04-29 |
| EP4048275A1 (en) | 2022-08-31 |
| JP2022553041A (ja) | 2022-12-21 |
| IL292332A (en) | 2022-06-01 |
| CN114746094A (zh) | 2022-07-12 |
| KR20220086627A (ko) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| MX2022005903A (es) | Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2. | |
| MY190034A (en) | Method of treating cancer associated with a ras mutation | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| MX2022004699A (es) | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| SG10201804151QA (en) | Anti-egfr antibodies and uses thereof | |
| MX2016011187A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda. | |
| MX2022013390A (es) | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. | |
| MX2016015436A (es) | Compuestos para tratar el cancer cerebral. | |
| TW201129380A (en) | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| MX2022002108A (es) | Metodo para tratar canceres asociados con kras. | |
| MX2019007801A (es) | Tratamiento de cáncer avanzado con expresión de her2. | |
| JOP20190103B1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| AU2019243283C1 (en) | Methods of treating ulcerative colitis | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
| BR112022001690A2 (pt) | Tratamento de tumores imunes evasivos | |
| MX2023002017A (es) | Composiciones y métodos para tratar cánceres positivos para ceacam. | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| MX2020010121A (es) | Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. | |
| NZ625758A (en) | Method for treating breast cancer |